AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 40
Description: A single dose administered subcutaneously (s.c., under the skin).
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 45
Description: A single dose administered subcutaneously (s.c., under the skin).
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 55
Description: A single dose administered subcutaneously (s.c., under the skin).
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: A single dose administered subcutaneously (s.c., under the skin).
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: A single dose administered subcutaneously (s.c., under the skin).
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: A single dose administered subcutaneously (s.c., under the skin).
Study NCT01868568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose administered subcutaneously (s.c., under the skin).
Study NCT00578903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
Study NCT00578903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
Study NCT00578903 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
Study NCT00578903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK-506
Description: FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
Study NCT00578903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
Study NCT00578903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10\^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10\^6 CD 34+ cells/kg should be collected, with a target of 10 X 10\^6/kg.
Study NCT01788761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplemented Group
Study NCT01788761 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control Group
Study NCT03703895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical AFX5931
Description: Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
Study NCT03703895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo
Description: Placebo Comparator, Topical Placebo.
Study NCT04104971 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood tests , abdominal US and doppler
Study NCT02278653 — intervention group
Intervention type: OTHER
Intervention: Questionnaires for the evaluation of Quality of Life
Description: 1. European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~2. Short Form (36) health survey~3. EORTC CR38~4. Vaizey score~5. Low Anterior Resection Syndrome (LARS) score~6. International Index of Erectile Function for men~7. International Prostate Symptom Score for men~8. Female Sexual Function Index for women
Study NCT02278653 — intervention group
Intervention type: OTHER
Intervention: Manometry
Description: Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
Study NCT03706846 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fasting
Description: fasting before gastrointestinal endoscopy
Study NCT01496456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
Study NCT01496456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caries management
Description: Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
Study NCT01496456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Caries management
Description: Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
Study NCT01985178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid Supplement
Study NCT00967122 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Band adjustment and specimen collection
Description: Clinical evaluation and sample collection before and after band adjustment
Study NCT03695081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Pathway Pharmacist intervention
Description: 1. Medication reconciliation at admission to hospital~2. Medication review post surgery~3. Optimised list of drugs in the discharge summary, in accordance with hospital procedures~4. Medication reconciliation, six weeks after discharge~5. Medication review, six weeks after discharge
Study NCT01569022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP Treatment for 12 weeks
Study NCT01569022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP Treatment for 12 weeks
Study NCT01569022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAD
Description: MAD Treatment for 12 weeks
Study NCT01569022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAD
Description: MAD Treatment for 12 weeks
Study NCT04694469 — intervention group
Intervention type: PROCEDURE
Intervention: Closed reduction and percutaneous pinning (CRPP)
Description: Operated for supracondylar humeral fractures
Study NCT01135342 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Diet and exercise
Description: Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
Study NCT01135342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Description: Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
Study NCT01135342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Standardized cognitive behavioral therapy for insomnia (8 classes)
Study NCT01135342 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Passion and Balance
Description: Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
Study NCT06375382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: We selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) 27,28 were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
Study NCT06375382 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture needles (0.35×40 mm) with flat tips (Hwato, Suzhou, China) were inserted towards the same acupoints to induce slight pain but without penetrating the skin. Sham moxibustion was made by igniting the same type of moxa sticks but fixing them at a distance of 8-10 cm from the skin of acupoints to maintain the temperature at 37 ± 1°C. Sham acupuncture and moxibustion were concomitantly performed for 30 min.
Study NCT03118180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 targeted chimeric antigen receptor T cells
Description: CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
Study NCT05540119 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Patients who undergo surgery are separately assessed
Study NCT01828658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strict bioimpedance guided dry weight prescription
Description: Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
Study NCT03059667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at 1200 mg IV every 3 weeks
Study NCT03059667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
Study NCT03059667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: In accordance with the summary of product characteristics.
Study NCT03059667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: In accordance with the summary of product characteristics.
Study NCT03139539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ioban
Study NCT03139500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61803534
Description: Participants will receive JNJ-61803534 tablets orally.
Study NCT03139500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT03139500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive single oral dose of midazolam.
Study NCT04361058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: At Day +50 (±10 days) post-allogeneic SCT, participants will be treated with Nivolumab. Nivolumab will be administered intravenously once every two weeks for a total of 4 treatments. Participants will initially receive nivolumab at a significantly reduced starting dose of 0.25 mg/kg. This dose was determined based on the incidence of increased aGVHD, which was noted after treatment post-SCT in previous studies. Nivolumab IV will be given every 2 weeks for 4 cycles. One dose of nivolumab is equivalent to one cycle. The first administration will be at Day +50 (±10 days), assuming the participant has not had any evidence of Grade II-IV aGVHD after allogeneic SCT and does not have any current evidence of any grade of aGVHD at the day of first application of nivolumab. Depending on emerging safety data, dose escalation cohorts will explore higher dose levels of nivolumab at 0.5 mg/kg and 1 mg/kg.
Study NCT01302899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg (Tablet)
Study NCT01302899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Aliskiren 150 mg Matching Placebo (Tablet)
Study NCT01302899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 25mg (Capsule)
Study NCT01302899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Hydrochlorothiazide (HCTZ)
Description: HCTZ 25mg (Capsule) Matching Placebo
Study NCT01302899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril 10mg (Tablet)
Study NCT02834975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab on Day 1 of each cycle.
Study NCT02834975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: * NACT: Paclitaxel on Day 1 of each cycle;~* ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol.
Study NCT02834975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV on Day 1 of each cycle.
Study NCT03506477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar® foam
Description: for 4 weeks
Study NCT03506477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: for 4 weeks
Study NCT02059239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
Study NCT02059239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m2 on Day -6
Study NCT02059239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 on days -5 to -2
Study NCT02059239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140mg/m2 on Day -1
Study NCT02059239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 200 mg/m2 on days -5 to -2
Study NCT02059239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
Study NCT02059239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Study NCT02059239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Study NCT02059239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
Study NCT03862638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: Yoga therapy is therapeutic application of yoga, specifically designed to treat the condition using physical posture, breathing exercises, guided relaxation and meditation.
Study NCT02861313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM LOC attachment
Description: CM LOC attachment
Study NCT02861313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ball attachment
Description: Ball attachment
Study NCT03055871 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Habit formation intervention
Description: In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
Study NCT03055871 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity planning intervention
Description: This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
Study NCT03733964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy - the mobilisation of joint segments L4-L5 and L5-S1 and mobilisation techniques for soft tissues (functional massage of soft tissues and skin relaxation using the methods of stretching).
Study NCT03733964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNF
Description: The PNF method - the movement patterns of the scapulae and the pelvis were used (anterior and posterior elevations and depression) along with the patterns of upper extremities (e.g. bending, abduction, outward rotation) and lower extremities (e.g. bending, abduction, inward rotation with bending of the knee joint).
Study NCT03733964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy + PNF
Description: Combination therapy - Manual therapy and Proprioceptive Neuromuscular Facilitation
Study NCT03733964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Traditional kinesiotherapy in the form of active slow exercises of back muscles, abdominal and gluteal muscles on a mat. The patients participated in a uniform treatment programme consisting of ten exercises. Each of the exercises was performed in a number of 20 repetitions.
Study NCT04816344 — intervention group
Intervention type: PROCEDURE
Intervention: Outpatient Anesthesia
Description: The inclusion criteria were children aged between 2 and 10 years, undergoing outpatient anaesthesia for elective MRI under sedation, and classified as American Society of Anesthesiologists (ASA) grade I-II. The study exclusion criteria were defined as difficult airway, allergies to the study drugs, asthma, severe central nervous system disease (eg, brain tumour, uncontrolled seizures), mental motor retardation, the application of another procedure after MRI sedation, and those whose parents declined to participate in the study.
Study NCT01268267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninja 2 Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
Study NCT00297167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Study NCT00297167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Study NCT00297167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Study NCT00297167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.